Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases (Q38105361)

28 August 2017

title

Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases (English)

1 reference

28 August 2017

David Lebwohl

1

1 reference

28 August 2017

Ozlem Anak

2

1 reference

28 August 2017

Tarek Sahmoud

3

1 reference

28 August 2017

Judith Klimovsky

4

1 reference

28 August 2017

Ingrid Elmroth

5

1 reference

28 August 2017

Tomas Haas

6

1 reference

28 August 2017

Joseph Posluszny

7

1 reference

28 August 2017

Stephen Saletan

8

1 reference

28 August 2017

William Berg

9

1 reference

28 August 2017

language of work or name

English

0 references

publication date

9 May 2013

1 reference

Annals of the New York Academy of Sciences

28 August 2017

published in

1 reference

28 August 2017

volume

1291

1 reference

28 August 2017

page(s)

14-32

1 reference

Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Research and innovation in the development of everolimus for oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Targeting the mTOR signaling network for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Everolimus: targeted therapy on the horizon for the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

The tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

In-stent stenosis: pathology and implications for the development of drug eluting stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Rapamycin in transplantation: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

TOR signaling in growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTÉ s

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Safety and efficacy of everolimus- versus sirolimus-eluting stents: a systematic review and meta-analysis of 11 randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Identification and characterization of a mitogen-activated S6 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Cloning of the mitogen-activated S6 kinase from rat liver reveals an enzyme of the second messenger subfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Correcting overall survival for the impact of crossover via a rank-preserving structural failure time (RPSFT) model in the RECORD-1 trial of everolimus in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Everolimus for tumor recurrence after surgical resection for subependymal giant cell astrocytoma associated with tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12122

Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.

21 January 2018

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.28.727

Identifiers

DOI

10.1111/NYAS.12122

1 reference

28 August 2017

1 reference